Home > Insider Trading > Filing (0001209191-21-001652)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178879	Amicus Therapeutics Inc.	FOLD	Pharmaceutical Preparations (2834)	200422823

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1400971	L Bradley Campbell	C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512	Chief Operating Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-12-31	7,617	$23.09	347,215	No	4	F	Direct
Common Stock	Disposition	2021-01-02	26,908	$23.09	320,307	No	4	F	Direct
Common Stock	Disposition	2021-01-03	13,974	$23.09	306,333	No	4	F	Direct
Common Stock	Acquisiton	2021-01-04	10,514	$6.45	316,847	No	4	M	Direct
Common Stock	Disposition	2021-01-04	10,514	$22.17	306,333	No	4	S	Direct
Common Stock	Acquisiton	2021-01-04	57,620	$0.00	363,953	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	F	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (right to buy)	Disposition	2021-01-04	10,514	$0.00	10,514	$6.45
Common Stock	Stock Options (right to buy)	Acquisiton	2021-01-04	92,792	$0.00	92,792	$21.78

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
48,679		2022-02-15	No	4	M	Direct
92,792		2031-01-04	No	4	A	Direct

Footnotes

The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $21.58 to $23.14 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
The Restricted Stock Units will vest in four equal annual installments beginning on January 4, 2022.
All of the options were fully vested and exercisable as of the transaction date.
These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.